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Abstract
A number of different methods exist to assess clinical stability, a key component of pneumonia management. We compared the prognostic
value of different stability criteria through a secondary analysis of the Edinburgh pneumonia study database. We studied four clinical stability
criteria (Halm’s criteria, the ATS criteria, CURB and 50% or more decrease in C-reactive protein from baseline). Outcomes included 30-day
mortality, need for mechanical ventilation or vasopressor support (MV/VS), development of a complicated pneumonia, and a combined
outcome of the above. A total of 1079 patients (49.8% male), with a median age of 68 years (IQR 53–80), were included. Ninety-three
patients (8.6%) died by day 30, 91 patients (8.4%) required MV/VS and 99 patients (9.2%) developed a complicated pneumonia. Patients with
increasing severity of pneumonia on admission, assessed by both CURB-65 and PSI, took a progressively longer time to achieve clinical
stability assessed by any method (p < 0.001 for all criteria). Halm’s criteria had the highest area under the curve (AUC) for prediction of
30-day mortality (AUC 0.95 (0.94–0.96)), need for MV/VS (AUC 0.96 (0.95–0.97)) and combined adverse outcome (AUC 0.96 (0.95–0.97)).
C-reactive protein had the highest area under the curve for complicated pneumonia (AUC 0.96 (0.95–0.97)). Adding C-reactive protein to
Halm’s criteria increased the area under the curve, but the difference was only statistically signiﬁcant for complicated pneumonia. All of the
criteria performed well in predicting adverse outcomes in patients with pneumonia. Halm’s criteria performed best when identifying patients
at low risk of complications.
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Introduction
Patients admitted with community acquired pneumonia (CAP)
have a 30-day mortality of about 5–15% and the inpatient
burden of CAP is rising, particularly amongst elderly patients
[1,2]. The use of severity assessment tools, such as the PSI [2]
and CURB-65 [3], has now been widely adopted as part of the
initial care for the management of CAP and they are critical for
early management decisions, such as home versus hospital care
and route of antibiotic delivery, as well as providing prognostic
information[2–6]. Assessment of treatment response and
thereby the concept of clinical stability, has emerged as a
crucial component of CAP management and a number of
methods exist that incorporate a combination of clinical and/or
laboratory markers [7–9]. Assessing clinical stability can
facilitate a number of essential decisions, such as intravenous
to oral antibiotic switch [10], duration of antibiotic therapy
[11,12], site of care within hospital settings and discharge from
hospital [13,14]. Furthermore, clinical stability can potentially
be used as a surrogate endpoint in clinical trials in CAP, as
clinical stability is associated with favourable clinical outcomes
[7,8]. This is especially useful in cohorts where mortality is
low, such as low-risk CAP patients, where clinical stability
could be used as a clinical endpoint in intervention trials, which
would otherwise require very large numbers of patients [15].
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A number of different methods exist to assess clinical
stability [7–9]; however, there are no studies that compare the
clinical utility of different stability criteria to predict clinical
outcomes in CAP. The aim of this study was to compare the
prognostic value of four different stability criteria and to
determine if adding CRP to these criteria would improve their
prognostic accuracy.
Methods
The present study describes a secondary analysis of the
Edinburgh pneumonia study database, a prospective observa-
tional study of consecutive unselected patients admitted to
NHS Lothian University Hospitals Division (Edinburgh, UK)
with a diagnosis of community-acquired pneumonia in 2005–
2009. The study was approved by the Lothian Research Ethics
Committee. Studies from this dataset, not related to clinical
stability criteria, have been previously published [16–18]. NHS
Lothian serves a population of 826 231 in a geographical area
of 1760 square kilometres in the east of Scotland.
Patients were included in the study if they presented with a
new inﬁltrate on a chest radiograph and had three or more of
the following symptoms or signs: cough, sputum production,
breathlessness, pleuritic chest pain, haemoptysis, fever, head-
ache, and signs consistent with pneumonia on chest ausculta-
tion. Exclusion criteria included: hospital-acquired pneumonia
(development of symptoms >48 h following admission or
discharge from an acute care facility <2 weeks prior to
admission), discharge from hospital within 24 h of admission/
assessment, active thoracic malignancy, immunosuppression,
pulmonary embolism on admission, and patients in whom active
treatment was not considered appropriate (palliative care).
All data reported in the study were collected by physicians
or medical students trained in the study methodology. Local
guidelines did not recommend any stability criteria for clinical
use during the study period.
Clinical stability criteria
Using the methodology originally described by Halm et al. [7],
we recorded daily laboratory and physiological variables, using
the most abnormal result over each 24-h period.
Halm’s criteria
Halm’s criteria measure clinical and physiological parameters
and were derived and validated in CAP populations [7,8]. We
calculated Halm’s criteria, which consist of seven clinical
variables (temperature  37.8°C, heart rate  100 beats/min,
respiratory rate  24 breaths/min, systolic blood pressure
 90 mmHg, O2 saturation  90% or arterial O2 ten-
sion 60 mmHg, normal mental status and normal oral
intake). These were assessed on admission, and daily until all
parameters were achieved, giving the time taken to clinical
stability. Where abnormalities of these variables were usual for
the patient (e.g. patients on long-term oxygen therapy or
patients with cognitive impairment leading to chronic abnor-
mal mental status), criteria were deemed to be met when the
patient returned to their usual level of functioning.
ATS stability criteria
The ATS criteria [9] for advising intravenous to oral switch for
antibiotics have been used to deﬁne clinical stability in a
number of studies [13,19]. They consist of four variables:
improvement in cough and shortness of breath, afebrile status
<37.8°C for  8 h, normalizing leukocyte count by 10% from
previous day, and adequate oral intake. Achieving all criteria
indicates clinical stability.
CURB
CURB-65 is a severity assessment tool for assessment on
admission [3]. Because patents with CURB-65 1 or 0 on
admission have a low mortality and are regarded as suitable for
outpatient management [4,20], we hypothesized that once the
CURB-65 criteria had normalized, patients would have a good
outcome, indicating clinical stability. We measured four of the
ﬁve variable criteria of CURB-65 (confusion, urea >7 mM/L,
respiratory rate  30 breaths/min and systolic blood pressure
<90 or diastolic blood pressure  60 mmHg). Normalization
of all four variable parameters indicated clinical stability.
C-reactive protein
There has been interest in the use of biomarkers in CAP;
previous studies have shown that a reduction in C-reactive
protein (CRP) to 50% of baseline is associated with good
clinical outcomes [21] and studies have assessed biomarkers
alone or in combination with stability criteria [8]. In this study,
CRP was measured on admission for all patients and repeated
routinely at days 3 and 4. Further measurements were made
routinely until clinical recovery. We calculated the percentage
decrease of CRP and a decrease of greater than 50% from
baseline was chosen as the cut-off based on previous studies
[21] and as recommended by the British Thoracic Society
guidelines [4].
Outcomes
The primary outcome of interest was 30-day mortality.
Secondary outcomes included need for mechanical ventilation
or vasopressor support (MV/VS) and development of a
complicated pneumonia (development of a complicated
parapneumonic effusion, empyema or pulmonary abscess).
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Survival status was assessed at 30 days for patients who were
still an inpatient at this time-point or at 6-week outpatient
follow-up if discharged before day 30. For any patient who did
not attend outpatient follow-up, survival status was obtained
by reviewing general practitioner records. Survival status was
conﬁrmed in 100% of patients included in the study. Missing
data were assumed to be normal, in accordance with the
methodology in previous studies [2]; there was less than 1% of
missing data in the study.
Statistical analysis
All data were analysed using SPSS version 21 for windows (SPSS
Inc., Chicago, IL, USA) and Graphpad Prism software (Graph-
pad, San Diego, CA, USA). Descriptive statistics of demo-
graphic and clinical variables are presented as median (IQR)
unless otherwise stated. Medians were compared using the
Mann–Whitney U-test for pairwise comparisons and the
Kruskal–Wallis test for comparing more than two groups.
The discriminatory value of each criterion from admission to
day 7 was compared using the receiver operator characteristic
curve. Sensitivity and speciﬁcities were calculated daily and
expressed as a summary ROC curve. The area under the ROC
curves was compared using the Hanley and MacNeil method
[22]. The discriminatory ability on each day was expressed
using the Youden index, a summary statistic calculated as
sensitivity + (speciﬁcity-1) [23]. A two-tailed p value of <0.05
was considered statistically signiﬁcant for each analysis.
Results
A total of 1079 patients (49.8% male), with a median age of
68 years (IQR 53–80), were included. Ninety-three patients
(8.6%) died by day 30, 91 patients (8.4%) had a need for
mechanical ventilation or vasopressor support (MV/VS) and 99
patients (9.2%) developed a complicated pneumonia. There
were 37 deaths in patients requiring MV/VS during the study
(40.7% of those requiring MV/VS). The mortality rate in
patients with complicated pneumonia was 9.1%. The median
length of stay was 5 days (IQR 3–11). Characteristics of the
study population are shown in Table 1.
Time taken to achieve clinical stability
The median time taken to achieve clinical stability for each
criterion stratiﬁed by the Pneumonia Severity Index (PSI) and
CURB-65 class on admission are shown in Tables 2 and 3. The
median time to clinical stability was 3 days for all criteria
(Table 2 and 3). Patients with more severe pneumonia on
admission assessed by both CURB-65 and PSI took a
signiﬁcantly longer time to reach clinical stability. This asso-
ciation was true for all the methods available to assess clinical
stability (p < 0.001 for all criteria).
Value of criteria for predicting subsequent outcome
We assessed whether the primary or secondary outcome
variables occurred prior to or after stability during the entire
hospital stay (Table 4). Achieving any of the criteria during
hospital admission resulted in a signiﬁcantly lower proportion
of patients meeting the primary and secondary outcomes.
TABLE 1. Characteristics of the study population
Demographic Study population (n = 1079)
Age (median (IQR)) 68 (53–80)
Gender (% male) 537 (49.8%)
Prior antibiotic treatment 135 (12.5%)
ICU admission 103 (9.5%)
PSI score (median (IQR)) 3 (2–4)
CURB-65 (median (IQR)) 2 (1–3)
Congestive cardiac failure 211 (19.6%)
Cerebrovascular disease 125 (11.6%)
Renal disease 69 (6.4%)
Chronic liver disease 54 (5.0%)
Diabetes mellitus 109 (10.1%)
COPD 251 (23.3%)
Positive microbiology (n = 314 (29.1%of entire cohort))a
S. pneumoniae 175 of 314 (55.7%)
H. inﬂuenzae 36 of 314 (11.5%)
S. aureus 29 of 314 (9.2%)
L. pneumophila 12 of 314 (3.8%)
M. pneumoniae 17 of 314 (5.4%)
Viruses 15 of 314 (4.8%)
Enterobacteriaceae 8 of 314 (2.5%)
Othersb 23 of 314 (7.3%)
aNumbers add up to more than 100% due to some patients growing more than
one pathogen.
bOther organisms included Moraxella catarrhalis, Chlamydophila pneumoniae,
Pseudomonas aeruginosa, and Streptococci other than S. pneumoniae.
TABLE 2. Time taken to achieve clinical stability (median (IQR)) in all patients and stratiﬁed by CURB-65
Stratiﬁcation N 30-day mortality n (%) Halm’s criteria ATS criteria CURB CRP 50% reduction
All patients 1079 93 (8.6%) 3 (2–6) 3 (2–5) 3 (0–5) 3 (3–6)
CURB-65 N 30-day mortality Halm’s criteria ATS criteria CURB CRP 50% reduction
0 199 2 (1.0%) 2 (0–3) 2 (1–3) 0 3 (2–4)
1 243 9 (3.7%) 2 (1–4) 2 (1–40 1 (0–3) 3 (2–5)
2 286 15 (5.2%) 3 (1–6) 3 (2–5) 3 (2–6) 3 (3–6)
3 206 25 (12.1%) 4 (2–7) 3 (2–7) 4 (2–6) 4 (3–8)
4 119 31 (26.1%) 7 (3–8) 5 (3–8) 5 (3–8) 6 (3–8)
5 26 11 (42. 3%)# 8 (7–8)# 8 (5–8)# 6 (3–8)# 7 (3–8)#
#p < 0.001 across CURB-65 severity class (Kruskal–Wallis test).
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Comparison between stability criteria
Figure 1 shows the discrimination of each stability criteria,
measured daily, for prediction of the outcome variables and a
combined outcome of any adverse outcome during hospital-
ization. Different criteria were optimal at different time-points;
C-reactive protein was of limited value before day 3 but
improved its discriminatory ability from day 3 onwards. The
CURB criteria had the highest Youden index on admission for
both 30-day mortality and MV/VS but were lower at later
time-points, consistent with this being an admission severity
score. Halm’s criteria and the ATS criteria were consistently
higher than CURB for the majority of outcomes (see Fig. 1).
The area under the receiver operator characteristic curve
was used to compare predictive indices across the ﬁrst 7 days
of hospitalization (Table 5). During this time, Halm’s criteria
had the highest area under the curve for prediction of 30-day
mortality, need for mechanical ventilation and combined
TABLE 3. Time taken to achieve clinical stability (median
(IQR)) stratiﬁed by PSI
PSI N
30-day
mortality
Halm’s
criteria
ATS
criteria CURB
CRP 50%
reduction
1 121 0 (0%) 1 (0–3) 2 (1–3) 0 3 (2–3)
2 228 2 (0.9%) 2 (1–3) 2 (1–4) 1 (0–4) 3 (2–4)
3 212 6 (2.8%) 3 (1–5) 2 (1–4) 2 (0–4) 3 (3–6)
4 317 31 (9.8%) 3 (2–7) 3 (2–6) 3 (1–6) 4 (3–7)
5 201 54 (26. 9%)# 7 (5–8)# 7 (3–8)# 5 (3–8)# 6 (4–8)#
#p < 0.001 across PSI severity class (Kruskal–Wallis test).
TABLE 4. Incidence of 30-day mortality, need for MV/IS or development of a complicated pneumonia stratiﬁed by achieving
clinical stability by all methods at any stage during hospital admission. N (entire cohort) = 1079
Criteria
30-day mortality, n = 93 MV/VS, n = 91 Complicated pneumonia, n = 99
Before stability (%)# After stability (%) Before stability (%)# After stability (%) Before stability (%)# After stability (%)
Halms criteria 88 (8.2) 5 (0.5) 88 (8.2) 3 (0.3) 91 (8.4) 8 (0.7)
ATS criteria 77 (7.1) 16 (1.5) 85 (7.9) 6 (0.6) 71 (6.6) 28 (2.6)
CURB criteria 74 (6.9) 18 (1.7) 83 (7.7) 8 (0.7) 63 (5.8) 36 (3.3)
CRP<50% baseline 85 (7.9) 8 (0.7) 85 (7.9) 6 (0.6) 95 (8.8) 4 (0.4)
#Stability not reached during admission. MV/VS = mechanical ventilation/vasopressor support.
FIG. 1. Discriminatory ability of stability criteria according to day of admission. Where indices are similar, overlapping points have been offset. Note
that there are no data for ATS criteria on day 0 as these criteria cannot be met on day 0. C-reactive protein data on day 0 are for those patients in
whom CRP was not elevated (<10 mg/L) on admission.
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adverse outcomes. C-reactive protein had the highest area
under the curve for complicated pneumonia.
Adding C-reactive protein to Halm’s criteria increased the
area under the curve, but the difference was only statistically
signiﬁcant for complicated pneumonia. Adding CRP to the ATS
criteria did not signiﬁcantly increase the AUC, except for
prediction of complicated pneumonia. Although the difference
was small, Halm’s criteria had a signiﬁcantly higher area under
the receiver operator characteristic curve compared with the
ATS criteria, CURB and C-reactive protein for the combined
outcome.
Discussion
Clinical stability has emerged as a key concept in commu-
nity-acquired pneumonia management [7–9]. Stability criteria
offer clinicians the ability to make conﬁdent treatment
decisions, such as conversion from intravenous to oral
antibiotics [10], shortening the duration of antibiotic therapy
[11,12] and reducing the length of hospital stay [7], whilst
highlighting early in their hospital course a cohort of patients in
whom there may be signiﬁcant pneumonia-related morbidity
and mortality [7,8].
This study has compared the predictive accuracy of four
deﬁnitions of clinical stability in community-acquired pneumo-
nia. All of the criteria predicted adverse outcomes, including
30-day mortality, MV/VS and complicated pneumonia. Overall,
Halm’s criteria were marginally better at identifying patients at
low risk of complications. The simpler ATS criteria had very
similar performance characteristics and overall both criteria
had excellent discrimination, with an area under the receiver
operator characteristic curve greater than 0.9. Broadly, our
study shows that both commonly used stability criteria are
valid, and physicians may use the criteria most suited to their
local circumstances [7–9].
Different criteria had different strengths and weaknesses. A
C-reactive protein that falls by 50% or more is associated with
a very low risk of complications in this study, but this marker is
less useful in the ﬁrst 2 days of hospital admission due to the
kinetics of C-reactive protein, which falls relatively slowly
compared with physiological parameters [21]. Consistent with
its known value as an admission severity score, the CURB
criteria were more discriminatory on admission than stability
criteria, but were less useful over subsequent days, suggesting
they are not as sensitive or speciﬁc a marker of treatment
response [3,6].
It has been suggested that biomarkers may be able to
improve the prognostic accuracy of stability criteria [8]. We
evaluated the biomarker C-reactive protein and whether this
was additive to the criteria based on clinical observations.
Several studies have shown that normalization of C-reactive
protein is associated with good clinical outcomes [21,24]. We
conﬁrmed that a reduction in CRP was associated with a low
mortality and need for MV/VS. Interestingly, CRP was the most
accurate marker at predicting development of complicated
pneumonia. We have previously found that a low CRP on
admission was associated with a low risk of complicated
parapneumonic effusion or empyema [25] and the association
between a persistently raised CRP and the development of
empyema has been long recognized [26]. This study suggests
that adding C-reactive protein to the Halms criteria improved
the AUC for predicting adverse outcomes but the difference
was only statistically signiﬁcant for prediction of complicated
pneumonia. Adding C-reactive protein to the ATS criteria did
not seem to bring signiﬁcant beneﬁts, perhaps because
normalization of the white cell count is already part of these
criteria.
We have also demonstrated that the time taken to achieve
clinical stability increases with the initial severity on admission,
assessed by either CURB-65 or PSI. Our data can inform us of
the mean time taken to achieve stability within each severity
assessment classiﬁcation and therefore we can look to provide
patients with more accurate prognostic assessment of the
likely course of their illness from admission severity. We have
also demonstrated that achieving clinical stability at any point
during the hospital course, assessed by any of the criteria
reported, is associated with a low incidence of subsequent
mortality, need for mechanical ventilation and/or vasopressor
support and complicated pneumonia.
TABLE 5. Area under the receiver operator characteristic curves for each criteria
Criteria 30-day mortality Need for MV/VS Complicated pneumonia Combined adverse outcome
Halm’s criteria 0.95 (0.94–0.96) 0.96 (0.95–0.97) 0.92 (0.91–0.93) 0.96 (0.95–0.97)
ATS criteria 0.94 (0.93–0.95) 0.95 (0.94–0.97) 0.8 (0.86–0.88)# 0.3 (0.93–0.95)#
CURB 0.2 (0.81–0.84)# 0.0 (0.89–0.91)# 0.74 (0.72–0.75) 0.3 (0.82–0.84)#
CRP<50% of baseline 0.6 (0.85–0.87)# 0.1 (0.90–0.92)# 0.94 (0.93–0.95) 0.1 (0.90–0.92)#
Halms and CRP 0.96 (0.95–0.97) 0.96 (0.95–0.97) 0.6 (0.95–0.97)# 0.97 (0.96–0.98)
ATS criteria and CRP 0.94 (0.93–0.95) 0.94 (0.93–0.95) 0.94 (0.93–0.95) 0.94 (0.3–0.95)
#indicates p < 0.05 compared with the area under the curve for Halm’s criteria. All other comparisons are not statistically signiﬁcant.
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Prognostic accuracy is not the only consideration in
deciding which criteria to use to deﬁne stability. Scores that
are simple and easy to use are more likely to be implemented
in clinical practice, and while Halm’s criteria had the highest
area under the curve in the present study they also contain
more parameters for measurement than the ATS criteria or a
simple blood test such as C-reactive protein. Conversely,
performing regular leukocyte count blood tests (ATS criteria)
and C-reactive protein measurements may not be practical or
desirable in certain settings. Physicians may therefore use our
data to decide the criteria that best suit their individual
circumstances.
Our ﬁndings have recently been mirrored in a retrospective
review of CAP patients discharged alive by Alberiti et al. [13].
They found that a delay in achieving clinical stability, deﬁned by
ATS criteria, results in a more adverse outcome in terms of
pneumonia-related complications and death. Several studies
have shown that patients discharged from hospital without
achieving clinical stability have a worse post-discharge out-
come [13,27,28].
Assessing clinical stability is also important because it has
implications for resource use, including the use of hospital
beds and the ability to safely discharge patients, and thereby
has an impact on the economic burden associated with CAP. A
tool that will allow a patient to be discharged with conﬁdence
that they are likely to have a good prognosis may reduce
inpatient CAP healthcare costs. Furthermore, clinical stability
criteria can be used as surrogate markers of clinical endpoints
in studies where the rate of mortality and other complications
is typically low, such as low-risk CAP patients [15].
In conclusion, we have demonstrated that all of the criteria
perform well in predicting an absence of adverse outcomes,
including 30-day mortality, MV/VS and complicated pneumonia,
when the criteria are met. Halm’s criteria were best at
identifying patients at low risk of complications but physicians
should adopt the criteria most suited to their local circum-
stances.
Transparency Declaration
All authors have no conﬂict of interest to declare.
References
1. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital
admissions for pneumonia, England. Emerg Infect Dis 2008; 14: 727–733.
2. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk
patients with community-acquired pneumonia. N Engl J Med 1997; 336:
243–250.
3. Lim WS, van der Eerden MM, Laing R et al. Deﬁning community
acquired pneumonia severity on presentation to hospital: an interna-
tional derivation and validation study. Thorax 2003; 58: 377–382.
4. British Thoracic Society Standards of Care Committee. BTS guidelines
for the management of CAP in adults. Thorax 2009; 64 (suppl 3): iii 1–55.
5. Chalmers JD, Singanayagam A, Akram AR, Choudhury G, Mandal P, Hill
AT. Safety and efﬁcacy of CURB65-guided antibiotic therapy in
community-acquired pneumonia. J Antimicrob Chemother 2011; 66:
416–423.
6. Chalmers JD, Singanayagam A, Akram AR et al. Severity assessment
tools for predicting mortality in hospitalised patients with commu-
nity-acquired pneumonia. Systematic review and meta-analysis. Thorax
2010; 65: 878–883.
7. Halm EA, Fine MJ, Marrie TJ et al. Time to clinical stability in patients
hospitalized with community-acquired pneumonia: implications for
practice guidelines. JAMA 1998; 279: 1452–1457.
8. Menendez R, Martinez R, Reyes S et al. Stability in community-acquired
pneumonia: one step forward with markers? Thorax 2009; 64: 987–992.
9. Mandell LA, Wunderink RG, Anzueto A et al. IDSA/ATS consensus
guidelines on the management of community-acquired pneumonia. Clin
Infect Dis 2007; 44 (suppl 2): S27–S72.
10. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from
intravenous to oral cephalosporins in the treatment of hospitalized
patients with community-acquired pneumonia. Arch Intern Med 1995;
155: 1273–1276.
11. el Moussaoui R, de Borgie CA, van den Broek P et al. Effectiveness of
discontinuing antibiotic treatment after three days versus eight days in
mild to moderate-severe community acquired pneumonia: randomised,
double blind study. BMJ 2006; 10(332): 1355.
12. Choudhury G, Mandal P, Singanayagam A, Akram AR, Chalmers JD, Hill
AT. 7 day antibiotic courses have similar efﬁcacy to prolonged courses
in severe community acquired pneumonia- a propensity-adjusted
analysis. Clin Microbiol Infect 2011; 17: 1852–1858.
13. Aliberti S, Peyrani P, Filardo G et al. Association between time to
clinical stability and outcomes after discharge in hospitalized patients
with community-acquired pneumonia. Chest 2011; 140: 482–488.
14. Capelastegui A, Espana PP, Bilbao A et al. Pneumonia: criteria for
patient instability on hospital discharge. Chest 2008; 134: 595–600.
15. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG.
Efﬁcacy of corticosteroids in community-acquired pneumonia: a
randomized double-blinded clinical trial. Am J Respir Crit Care Med
2010; 181: 975–982.
16. Chalmers JD, Taylor J, Mandal P et al. Validation of the IDSA/ATS
minor criteria for ICU admission in community-acquired pneumonia
patients without major criteria or contraindications to ICU care. Clin
Infect Dis 2011; 53: 503–511.
17. Chalmers JD, Singanayagam A, Hill AT. Systolic blood pressure is
superior to other haemodynamic predictors of outcome in community
acquired pneumonia. Thorax 2008; 63: 698–702.
18. Chalmers JD, Singanayagam A, Hill AT. Predicting the Need for
Mechanical Ventilation and/or vasopressor support for young adults
admitted with community-acquired pneumonia. Clin Infect Dis 2008; 47:
1571–1574.
19. Arnold FW, Brock GN, Peyrani P et al. Predictive accuracy of the
pneumonia severity index vs CRB-65 for time to clinical stability:
results from the Community-Acquired Pneumonia Organization
(CAPO) International Cohort Study. Respir Med 2010; 104: 1736–
1743.
20. Akram AR, Chalmers JD, Hill AT. Predicting mortality with severity
assessment tools in out-patients with community-acquired pneumonia.
QJM 2011; 104: 871–879.
21. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an
independent predictor of severity in community-acquired pneumonia.
Am J Med 2008; 121: 219–225.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 1174–1180
CMI Akram et al. Evaluation of clinical stability in pneumonia 1179
22. Hanley JA, McNeil BJ. A method comparing the areas under receiver
operating characteristic curves derived from the same set of cases.
Radiology 1983; 148: 839–843.
23. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32–35.
24. Coelho L, Povoa P, Almeida E et al. Usefulness of C-reactive protein in
monitoring the severe community-acquired pneumonia clinical course.
Crit Care 2007; 11: R92.
25. Chalmers JD, Singanayagam A, Scally C, Fawzi A, Murray MP, Hill AT.
Risk Factors for complicated parapneumonic effusion and empyema on
presentation to hospital with community acquired pneumonia. Thorax
2009; 64: 592–597.
26. Icard P, Fleury JP, Regnard JF et al. Utility of C-reactive protein
measurements for empyema diagnosis after pneumonectomy. Ann
Thorac Surg 1994; 57: 933–936.
27. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability
on Hospital Discharge and the Risk of Adverse Outcomes in Patients
With Pneumonia. Arch Intern Med 2002; 162: 1278–1284.
28. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and
risk factors for rehospitalization of patients hospitalized with commu-
nity-acquired pneumonia. Clin Infect Dis. 2008; 46: 550–556.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 1174–1180
1180 Clinical Microbiology and Infection, Volume 19 Number 12, December 2013 CMI
